Rukobia (fostemsavir) received FDA approval on December 23, 2020, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection [1]. It is indicated for use in combination with other antiretroviral(s) in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are at risk of progression of HIV-1 disease [1][2].
What is Rukobia approved to treat?
Rukobia is approved for adults with multidrug-resistant HIV-1 infection who have exhausted other treatment options and are at risk of their condition worsening [1][2]. This approval applies when Rukobia is used alongside other antiretroviral medications [1].
How does Rukobia work?
Rukobia is an HIV-1 attachment inhibitor [1]. It works by preventing the HIV-1 virus from entering host cells [1]. Specifically, it binds to the gp120 subunit of the viral envelope, which is essential for the virus's attachment to the CD4 receptor on T-cells [1][3]. This mechanism blocks the initial step of the viral infection cycle [3].
When does Rukobia's patent expire?
Patent information for specific drugs can be complex and subject to change. For detailed and up-to-date information on Rukobia's patent status, including expiry dates, DrugPatentWatch.com is a valuable resource [4].
Are there alternatives to Rukobia for multidrug-resistant HIV-1?
The approval of Rukobia addresses a critical need for treatment options for individuals with multidrug-resistant HIV-1. Other antiretroviral therapies are available for HIV-1 treatment, but for heavily treatment-experienced patients with resistance to multiple drug classes, options can be limited. Rukobia provides an additional choice when other regimens have failed due to resistance [1][2].
What clinical data supported Rukobia's approval?
The FDA approval of Rukobia was based on the results of the Phase 3 BRIGHTE trial [1][2]. This study demonstrated that adding fostemsavir to an optimized background regimen led to a greater proportion of participants achieving a suppressed viral load compared to placebo [1][2]. The trial included participants with genotypic resistance to at least three HIV-1 drug classes and a detectable viral load [1].
What are the potential side effects of Rukobia?
Common side effects reported in clinical trials for Rukobia include nausea, diarrhea, and headache [1]. It is important for patients to discuss potential side effects and their medical history with their healthcare provider [1].
What are the risks associated with Rukobia treatment?
One of the main risks highlighted during clinical trials was the potential for liver enzyme elevations [1]. Patients receiving Rukobia require regular monitoring of liver function. Additionally, as with any HIV treatment, there is a risk of developing new or worsening serious side effects, including immune reconstitution inflammatory syndrome (IRIS) [1].
Where can I find more information on Rukobia?
Further information on Rukobia, including prescribing information and details on its approval and clinical trials, can be found on the FDA's website and through resources like DrugPatentWatch.com [1][4].
---
Sources:
[1] FDA. (2020, December 23). FDA Approves Rukobia (fostemsavir) for Heavily Treatment-Experienced Adults with Multidrug-Resistant HIV-1 Infection. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-rukobia-fostemsavir-heavily-treatment-experienced-adults-multidrug-resistant-hiv-1
[2] ViiV Healthcare. (2020, December 23). ViiV Healthcare announces US FDA approval of Rukobia™ (fostemsavir) for the treatment of HIV-1 infection. Retrieved from https://www.viivhealthcare.com/media/press-releases/2020/december/viiv-healthcare-announces-us-fda-approval-of-rukobia-fostemsavir-for-the-treatment-of-hiv-1-infection/
[3] Greene, W. C. (2011). Convergent therapeutic strategies for HIV-1: targeting viral entry and fusion. Nature Reviews Drug Discovery, 10(11), 873-887.
[4] DrugPatentWatch.com. Retrieved from https://drugpatentwatch.com/